A health benefit plan that provides coverage for chimeric antigen receptor T-cell therapy must provide coverage for chimeric antigen receptor T-cell therapy that is:
(1) medically necessary; and
(2) administered by a health care provider that is:
(A) qualified as a certified health care facility in accordance with the procedure for the chimeric antigen receptor T-cell therapy product license approved by the United States Food and Drug Administration; and
(B) participating in the health benefit plan's network with respect to any other service.